David Kerstein
Cambridge Intellectual Property (United Kingdom) · 70 works · 2,861 citations · h-index 20
Top works
- Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
- Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).
- Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
- Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.
- Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
- OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
- First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).
- Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
- Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
- Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.
- Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
- The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
- Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
- Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
- Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer